TheEdgeResearch
Home / Stocks / RDHL

RedHill Biopharma Ltd. (RDHL)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$0.50 ▼ -5.36%
Market Cap
$1.6M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
4.95
52-Wk Range
0.5-2.79
CEO
Dror Ben-Asher
Country
IL
Currency
USD

RedHill Biopharma Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Tel Aviv, TA, IL. The stock last traded at $0.50, down 5.36% on the session, giving a market capitalisation of $1.6M. On trailing twelve-month figures it carries a trailing P/E of -0.25, a net margin of -101.3%. Its beta of 4.95 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.25
Price / Sales
0.39
Price / Book
0.21
EV / EBITDA
0.32
Gross margin
60.6%
Operating margin
-107.3%
Net margin
-101.3%
Return on equity
—
Debt / equity
0.25
Current ratio
0.34
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
13
IPO date
2013-01-07
Headquarters
Tel Aviv, TA, IL
About RedHill Biopharma Ltd.

RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.

Comparable companies

RedHill Biopharma Ltd. is most often compared with the following Healthcare names:

AKANBGMSBNBXCNSPFLGCGCTKIMCCJAGXMSPRSXTP
More research on RDHL
RDHL technical analysis RDHL TheEdge Score Compare against peers
Open full interactive analysis & DCF →